iPSC-derived pancreatic islet cells (Laverock Therapeutics Ltd)

N/A

Report date: 2025/04/11 14:37:44

Base Information

Drug NameiPSC-derived pancreatic islet cells (Laverock Therapeutics Ltd)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Induced pluripotent stem cells therapyCell and gene therapy > Cell therapy > Stem cell therapy > Pancreatic stem cell therapy
Mechanisms of ActionStem cell replacements
TargetsNot applicable
Therapy Area/IndicationsDiabetes Mellitus, Type 1
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesLaverock Therapeutics Ltd
China Registration ClassN/A

Develop Information

Active CompaniesLaverock Therapeutics Ltd
Inactive CompaniesN/A
Active IndicationsDiabetes Mellitus, Type 1
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A